Title of article :
Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibso
Author/Authors :
Davies، نويسنده , , Christina، نويسنده ,
